Dr. Reddy's Laboratories Limited announced its launch of Doxycycline Capsules, 40 mg in the U.S. market, a therapeutic generic equivalent of ORACEA (doxycycline, USP) Capsules, 40 mg approved by the U.S. Food and Drug Administration (USFDA). Dr. Reddy?s Doxycycline Capsules, 40 mg, are supplied in bottle counts of 30. Each capsule contains: 26 mg immediate-release pellets and 14 mg delayed-release pellets equivalent to 40 mg of anhydrous doxycycline, USP.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5,815 INR | +0.27% | -1.75% | +0.29% |
05-16 | Asian Equities Traded in the US as American Depositary Receipts Ease in Thursday Trading | MT |
05-15 | Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.29% | 11.59B | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- DRREDDY Stock
- News Dr. Reddy's Laboratories Limited
- Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg in the U.S